Cover Image

Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5

Abstract The cytochrome P450 3As (CYP3As) are abundantly expressed in the liver and metabolize many commonly prescribed medications. Their expression is highly variable between individuals with little known genetic cause. Despite extensive investigation, cis‐acting genetic elements that control the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joseph M. Collins (Author), Adaeze C. Nworu (Author), Somayya J. Mohammad (Author), Liang Li (Author), Chengcheng Li (Author), Chuanjiang Li (Author), Ethan Schwendeman (Author), Mattew Cefalu (Author), Mahmoud Abdel‐Rasoul (Author), Jessie W. Sun (Author), Sakima A. Smith (Author), Danxin Wang (Author)
Format:	Book
Published:	Wiley, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples
by: Joseph M. Collins, et al.
Published: (2023)

<it>CYP3A4 </it>and <it>CYP3A5 </it>genotyping by Pyrosequencing
by: McLeod Howard L, et al.
Published: (2005)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
by: David Damoiseaux, et al.
Published: (2022)

CYP3A and CYP2C19 activity in urine in relation to CYP3A4, CYP3A5, and CYP2C19 polymorphisms in Russian peptic ulcer patients taking omeprazole
by: Denisenko NP, et al.
Published: (2018)

Induction of CYP3A by morroniside in rats
by: Shan Xiong, et al.
Published: (2015)

Genome-wide microRNA profiles identify miR-107 as a top miRNA associating with expression of the CYP3As and other drug metabolizing cytochrome P450 enzymes in the liver
by: Marwa Tantawy, et al.
Published: (2022)

Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome
by: Min Li, et al.
Published: (2018)

Association of CYP3A4*1B, CYP3A4*22 and CYP3A5*3 polymorphisms carriage with efficacy and safety of tamsulosin in patients with benign prostatic hyperplasia
by: Sh. P. Abdullaev, et al.
Published: (2024)

Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer
by: Sm Faysal Bellah, et al.
Published: (2023)

The Modulatory Role of CYP3A4 in Dictamnine-Induced Hepatotoxicity
by: Zhuo-Qing Li, et al.
Published: (2018)

The Dynamic Effect of Non-CYP3A4-Metabolized and CYP3A4-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
by: Hong Ting Shi, et al.
Published: (2021)

Pharmacokinetics of asciminib in the presence of CYP3A or P‐gp inhibitors, CYP3A inducers, and acid‐reducing agents
by: Matthias Hoch, et al.
Published: (2022)

Identification of Selective CYP3A7 and CYP3A4 Substrates and Inhibitors Using a High-Throughput Screening Platform
by: Md Kabir, et al.
Published: (2022)

Expression of CYP3A4 mRNA Is Correlated With CYP3A4 Protein Level and Metabolic Activity in Human Liver
by: Minoru Watanabe, et al.
Published: (2004)

Influence of Genetic Polymorphisms in CYP3A5, CYP3A4, and MDR1 on Tacrolimus Metabolism after kidney transplantation
by: Mirgul Bayanova, et al.
Published: (2024)

Cross-species variability in lobular geometry and cytochrome P450 hepatic zonation: insights into CYP1A2, CYP2D6, CYP2E1 and CYP3A4
by: Mohamed Albadry, et al.
Published: (2024)

Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
by: Jim J. Xiao, et al.
Published: (2019)

CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride
by: Diana María Campodónico, et al.
Published: (2022)

Formation of CYP3A‐specific metabolites of ibrutinib in vitro is correlated with hepatic CYP3A activity and 4β‐hydroxycholesterol/cholesterol ratio
by: Jonghwa Lee, et al.
Published: (2023)

Ionic Liquid 1-Octyl-3-Methylimidazolium (M8OI) Is Mono-Oxygenated by CYP3A4 and CYP3A5 in Adult Human Liver
by: Alistair C. Leitch, et al.
Published: (2024)

Genetic polymorphisms of CYP2B6*6, CYP2C8*3 and CYP2D6*4 in vivax malaria patients from Brazilian Amazon
by: José Pereira de Moura Neto, et al.
Published: (2023)

Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
by: Stephania Contreras-Castillo, et al.
Published: (2021)

Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function
by: Alison E. Fohner, et al.
Published: (2021)

Pregnancy related hormones increase CYP3A mediated buprenorphine metabolism in human hepatocytes: a comparison to CYP3A substrates nifedipine and midazolam
by: Muluneh M. Fashe, et al.
Published: (2023)

Porcine foetal and neonatal CYP3A liver expression
by: Marie Louise Hiort Hermann, et al.
Published: (2011)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug-Drug-Gene Interaction Predictions
by: Helena Leonie Hanae Loer, et al.
Published: (2022)

Impact of CYP2C19, CYP3A4, ABCB1, and FMO3 genotypes on plasma voriconazole in Thai patients with invasive fungal infections
by: Sumonrat Chuwongwattana, et al.
Published: (2020)

Baicalein inhibits the pharmacokinetics of simvastatin in rats via regulating the activity of CYP3A4
by: Meng Meng, et al.
Published: (2021)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
by: Jin-Woo Park, et al.
Published: (2021)

Utilization of Human Liver Microsomes to Explain Individual Differences in Paclitaxel Metabolism by CYP2C8 and CYP3A4
by: Ryoko Taniguchi, et al.
Published: (2005)

Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum
by: Decker BS, et al.
Published: (2013)

Exploring the Effect of Compound Glycyrrhizin and Silybinin on the Metabolism of Pexidartinib in Rats Based on CYP3A4 and CYP2C9
by: Yanding Su, et al.
Published: (2023)

<i>CYP3A5*3</i> and <i>CYP3A4*22</i> Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach
by: Zeyar Mohammed Ali, et al.
Published: (2023)

PBPK perspective on alternative CYP3A4 inducers for rifampin
by: Kuan‐Fu Chen, et al.
Published: (2022)

Reductive metabolism of oxymatrine is catalyzed by microsomal CYP3A4
by: Liu W, et al.
Published: (2015)

Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated Metabolism
by: Nicola Ferri, et al.
Published: (2023)

A Robust and Fast/Multiplex Pharmacogenetics Assay to Simultaneously Analyze 17 Clinically Relevant Genetic Polymorphisms in <i>CYP3A4</i>, <i>CYP3A5</i>, <i>CYP1A2</i>, <i>CYP2C9</i>, <i>CYP2C19</i>, <i>CYP2D6</i>, <i>ABCB1,</i> and <i>VKORC1</i> Genes
by: Camille Tron, et al.
Published: (2022)

In vitro effects and in silico analysis of newly synthetized pyrrole derivatives on the activity of different isoforms of Cytochrome P450: CYP1A2, CYP2D6 and CYP3A4
by: Borislav Angelov, et al.
Published: (2022)

Enzymatic Activities of CYP3A4 Allelic Variants on Quinine 3-Hydroxylation In Vitro
by: Xiao-Yang Zhou, et al.
Published: (2019)

Prediction of the drug-drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib
by: Loeckie De Zwart, et al.
Published: (2021)